TY - JOUR
T1 - Development of a multiomics database for personalized prognostic forecasting in head and neck cancer
T2 - The Big Data to Decide EU Project
AU - Cavalieri, Stefano
AU - De Cecco, Loris
AU - Brakenhoff, Ruud H.
AU - Serafini, Mara Serena
AU - Canevari, Silvana
AU - Rossi, Silvia
AU - Lanfranco, Davide
AU - Hoebers, Frank J. P.
AU - Wesseling, Frederik W. R.
AU - Keek, Simon
AU - Scheckenbach, Kathrin
AU - Mattavelli, Davide
AU - Hoffmann, Thomas
AU - Lopez Perez, Laura
AU - Fico, Giuseppe
AU - Bologna, Marco
AU - Nauta, Irene
AU - Leemans, C. Rene
AU - Trama, Annalisa
AU - Klausch, Thomas
AU - Berkhof, Johannes Hans
AU - Tountopoulos, Vasilis
AU - Shefi, Ron
AU - Mainardi, Luca
AU - Mercalli, Franco
AU - Poli, Tito
AU - Licitra, Lisa
AU - BD2Decide Consortium
PY - 2021/2
Y1 - 2021/2
N2 - Background Despite advances in treatments, 30% to 50% of stage III-IV head and neck squamous cell carcinoma (HNSCC) patients relapse within 2 years after treatment. The Big Data to Decide (BD2Decide) project aimed to build a database for prognostic prediction modeling.Methods Stage III-IV HNSCC patients with locoregionally advanced HNSCC treated with curative intent (1537) were included. Whole transcriptomics and radiomics analyses were performed using pretreatment tumor samples and computed tomography/magnetic resonance imaging scans, respectively.Results The entire cohort was composed of 71% male (1097)and 29% female (440): oral cavity (429, 28%), oropharynx (624, 41%), larynx (314, 20%), and hypopharynx (170, 11%); median follow-up 50.5 months. Transcriptomics and imaging data were available for 1284 (83%) and 1239 (80%) cases, respectively; 1047 (68%) patients shared both.Conclusions This annotated database represents the HNSCC largest available repository and will enable to develop/validate a decision support system integrating multiscale data to explore through classical and machine learning models their prognostic role.
AB - Background Despite advances in treatments, 30% to 50% of stage III-IV head and neck squamous cell carcinoma (HNSCC) patients relapse within 2 years after treatment. The Big Data to Decide (BD2Decide) project aimed to build a database for prognostic prediction modeling.Methods Stage III-IV HNSCC patients with locoregionally advanced HNSCC treated with curative intent (1537) were included. Whole transcriptomics and radiomics analyses were performed using pretreatment tumor samples and computed tomography/magnetic resonance imaging scans, respectively.Results The entire cohort was composed of 71% male (1097)and 29% female (440): oral cavity (429, 28%), oropharynx (624, 41%), larynx (314, 20%), and hypopharynx (170, 11%); median follow-up 50.5 months. Transcriptomics and imaging data were available for 1284 (83%) and 1239 (80%) cases, respectively; 1047 (68%) patients shared both.Conclusions This annotated database represents the HNSCC largest available repository and will enable to develop/validate a decision support system integrating multiscale data to explore through classical and machine learning models their prognostic role.
KW - big data
KW - head and neck cancer
KW - prognostic models
KW - radiomics
KW - transcriptomics
KW - QUALITY-OF-LIFE
KW - HUMAN-PAPILLOMAVIRUS
KW - EUROPEAN-ORGANIZATION
KW - OROPHARYNGEAL CANCER
KW - CARCINOMA PATIENTS
KW - SURVIVAL
KW - VALIDATION
KW - COMORBIDITY
KW - PREDICTION
KW - SIGNATURE
U2 - 10.1002/hed.26515
DO - 10.1002/hed.26515
M3 - Article
C2 - 33107152
VL - 43
SP - 601
EP - 612
JO - Head and Neck-Journal for the Sciences and Specialties of the Head and Neck
JF - Head and Neck-Journal for the Sciences and Specialties of the Head and Neck
SN - 1043-3074
IS - 2
ER -